Vaxzevria (previously COVID-19 Vaccine AstraZeneca) 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

vaxzevria (previously covid-19 vaccine astrazeneca)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - cjepiva - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

COVID-19 VACCINE JANSSEN najmanje 8.92 log10 Inf.U/0.5ml Suspenzija za injekciju 黑山共和国 - 克罗地亚文 - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

covid-19 vaccine janssen najmanje 8.92 log10 inf.u/0.5ml suspenzija za injekciju

druŠtvo sa ograniČenom odgovornoŠĆu "inpharm co" podgorica - vakcina protiv covid-19 (ad26.cov2-s, rekombinantna) - suspenzija za injekciju - najmanje 8.92 log10 inf.u/0.5ml

COVID-19 VACCINE JANSSEN najmanje 8.92 log10 Inf.U/0.5ml Suspenzija za injekciju 黑山共和国 - 克罗地亚文 - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

covid-19 vaccine janssen najmanje 8.92 log10 inf.u/0.5ml suspenzija za injekciju

druŠtvo sa ograniČenom odgovornoŠĆu "inpharm co" podgorica - vakcina protiv covid-19 (ad26.cov2-s, rekombinantna) - suspenzija za injekciju - najmanje 8.92 log10 inf.u/0.5ml

RotaTeq 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

rotateq

merck sharp & dohme b.v. - rotavirus serotip g1, serotip g2, serotip g3, serotip g4, serotip p1 - immunization; rotavirus infections - vaccines, viral vaccines - rotateq je indicirana za aktivnu imunizaciju dojenčadi od dobi od šest tjedana do 32 tjedna za prevenciju gastroenteritisa zbog infekcije rotavirusom. rotateq koristi se na temelju službenih preporuka.

PreHevbri 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

prehevbri

vbi vaccines b.v. - hepatitis b površinski antigen - hepatitis b - cjepiva - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Bexsero 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

bexsero

gsk vaccines s.r.l. - vanjska membrana везикулы od менингококк grupe b (soj 98/254 nc), рекомбинантный менингококк grupe u fhbp sintezu proteina, rekombinantnog менингококк grupe b nada protein, рекомбинантный менингококк grupe u nhba sintezu proteina - meningitis, meningokokal - meningokokna cjepiva - aktivna imunizacija protiv invazivnih bolesti uzrokovanih sojima neisseria meningitidis serogroup-b.

Pandemic Influenza Vaccine H5N1 Baxter AG 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 baxter ag

resilience biomanufacturing ireland limited - cjepivo protiv influence (cijeli virion, inaktivirano) koji sadrži antigen: a / vietnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - cjepiva - profilakcija gripe u službeno prijavljenoj pandemijskoj situaciji. cjepivo protiv influence pandemije treba koristiti u skladu s službenim smjernicama.

Nuvaxovid 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

nuvaxovid

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Bimervax 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

bimervax

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - cjepiva - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.